M&T Bank Corp Invests $52.72 Million in Revolution Medicines, Inc. $RVMD

M&T Bank Corp bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 661,929 shares of the company’s stock, valued at approximately $52,723,000.

Several other institutional investors have also made changes to their positions in the company. Signaturefd LLC increased its position in shares of Revolution Medicines by 33.1% in the fourth quarter. Signaturefd LLC now owns 656 shares of the company’s stock worth $52,000 after acquiring an additional 163 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Revolution Medicines by 44.7% in the fourth quarter. Farther Finance Advisors LLC now owns 751 shares of the company’s stock worth $60,000 after acquiring an additional 232 shares in the last quarter. CWM LLC increased its position in shares of Revolution Medicines by 51.6% in the fourth quarter. CWM LLC now owns 702 shares of the company’s stock worth $56,000 after acquiring an additional 239 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Revolution Medicines by 45.1% in the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after acquiring an additional 260 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in shares of Revolution Medicines by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 54,143 shares of the company’s stock worth $2,528,000 after acquiring an additional 336 shares in the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

Revolution Medicines Stock Performance

Shares of RVMD opened at $141.50 on Thursday. The company’s 50 day moving average price is $106.04 and its 200 day moving average price is $88.28. Revolution Medicines, Inc. has a 52 week low of $34.00 and a 52 week high of $155.70. The company has a market capitalization of $28.04 billion, a PE ratio of -23.94 and a beta of 1.01. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter in the previous year, the firm earned ($1.12) EPS. Research analysts expect that Revolution Medicines, Inc. will post -7.57 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Stifel Nicolaus reissued a “buy” rating on shares of Revolution Medicines in a research report on Monday. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research report on Tuesday. UBS Group began coverage on shares of Revolution Medicines in a research report on Friday, February 27th. They set a “buy” rating on the stock. Finally, Evercore reaffirmed an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $78.94.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Phase 3 RASolute 302 reported an unprecedented overall survival benefit for daraxonrasib and the full trial results will be presented in a Plenary Session at ASCO (May 31). This is a major clinical and commercial inflection point if the detailed data and safety profile hold up. Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results
• Positive Sentiment: Updated Phase 1/2 daraxonrasib data in first-line metastatic pancreatic cancer will be presented at AACR (late-breaking mini-symposium and poster), reinforcing momentum across both later- and earlier-line programs. Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib
• Positive Sentiment: Preclinical data on RM-055 (a mutant-targeted catalytic RAS(ON) inhibitor) show activity across resistant models and multiple tumor types — adds depth to the pipeline beyond daraxonrasib. Revolution Medicines to Present Preclinical Data on RM-055
• Positive Sentiment: Multiple brokerages (HC Wainwright, Stifel and others) have reiterated or maintained Buy/Outperform ratings and elevated price targets recently, supporting continued analyst optimism around commercialization potential. HC Wainwright Buy Rating Reaffirmed (Benzinga)
• Neutral Sentiment: Several Revolution-sponsored abstracts (real‑world analyses, safety/efficacy in later lines) were accepted for publication — useful for market narrative but less likely to move the stock than pivotal OS/PFS readouts. Additional Accepted Abstracts (GlobeNewswire)
• Negative Sentiment: Notable insider selling and large institutional position reductions have been reported in recent quarters — heavy insider sales and major funds trimming can exert selling pressure and reduce investor confidence. Quiver / Insider & Institutional Activity
• Negative Sentiment: Daraxonrasib remains investigational and regulatory approval, full safety readouts, and commercialization execution are still future events — these risks (plus the company’s prior EPS misses and cash burn profile) keep the story binary and can drive volatile trading. Regulatory & Forward-Looking Risks

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 4,583 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $455,916.84. Following the completion of the sale, the chief operating officer directly owned 157,570 shares in the company, valued at $15,675,063.60. The trade was a 2.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Xiaolin Wang sold 2,010 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the completion of the sale, the insider owned 116,063 shares of the company’s stock, valued at $11,545,947.24. This trade represents a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 184,592 shares of company stock valued at $24,499,532. Insiders own 8.20% of the company’s stock.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.